Anna Madej, MD
Internal Medicine · Sunnyside, WANPI 1194834705
Payments from drug & device makers
Across 300 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$983
- AbbVie$602
- Bayer$563
- Boehringer Ingelheim$462
- Sumitomo Pharma America, Inc.$462
- Novartis$422
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,201100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $983 |
| AbbVie | 30 | $602 |
| Bayer | 27 | $563 |
| Boehringer Ingelheim | 21 | $462 |
| Sumitomo Pharma America, Inc. | 18 | $462 |
| Novartis | 19 | $422 |
| Novo Nordisk | 24 | $407 |
| Pfizer | 19 | $328 |
| Johnson & Johnson | 9 | $208 |
| Sunovion Pharmaceuticals Inc. | 9 | $185 |
| Electromed, Inc. | 3 | $154 |
| Lilly USA, LLC | 8 | $142 |
| Otsuka America Pharmaceutical, Inc. | 6 | $140 |
| Dexcom, Inc. | 6 | $135 |
| GSK | 5 | $129 |
| Amgen | 7 | $125 |
| Xeris Pharmaceuticals, Inc. | 6 | $118 |
| Astellas Pharma US Inc | 3 | $77 |
| Mylan Specialty L.p. | 4 | $64 |
| Sanofi-aventis U.S. LLC | 4 | $62 |
| Merck | 3 | $55 |
| E.r. Squibb & Sons, L.L.C. | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $45 |
| CMP Pharma, Inc. | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 1 | $31 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Alk-abello, Inc | 1 | $24 |
| Lundbeck LLC | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Sobi, Inc | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| BD | 1 | $14 |
| Abbott | 1 | $13 |
| Tactile Systems Technology Inc | 1 | $12 |
How this compares
$6,201 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 152 | $168,805 |
| JardianceEmpagliflozin | 131 | $116,819 |
| TrulicityDulaglutide | 90 | $104,158 |
| EliquisApixaban | 133 | $91,271 |
| MounjaroTirzepatide | 67 | $71,785 |
| FarxigaDapagliflozin Propanediol | 48 | $53,490 |
| XareltoRivaroxaban | 54 | $39,589 |
| LinzessLinaclotide | 32 | $33,036 |
| GemtesaVibegron | 53 | $28,308 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $15,078 |
| MyrbetriqMirabegron | 24 | $15,069 |
| Bydureon BciseExenatide Microspheres | 17 | $14,594 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $13,617 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,580 |
| RybelsusSemaglutide | 12 | $11,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $407 | $180,365164 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $142 | $175,943157 claims |
| Boehringer IngelheimJardiance | $462 | $116,819131 claims |
| PfizerEliquis | $328 | $91,271133 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Nexium | $983 | $73,40170 claims |
| AbbVieLinzess, Creon | $602 | $42,30746 claims |
| Johnson & JohnsonXarelto | $208 | $39,58954 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $462 | $28,30853 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $129 | $22,01132 claims |
| Astellas Pharma US IncMyrbetriq | $77 | $15,06924 claims |
| NovartisEntresto | $422 | $9,21212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Sunnyside
- Sabrina BenjaminOlympia$7.9M
- Ryan AhernSeattle$7.3M
- Eric KleinOlympia$2.4M
- Scott RamseySeattle$2M
- Vidya MenonTacoma$1.8M
- Peter ShalitSeattle$1.8M
- Yuan Po TuEverett$1.6M
- Peiqing QianSeattle$1.5M
- Radica AlicicSpokane$1.5M
- Shelly KhuranaLynnwood$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.